Sarah Atkinson
General Practice · Rochester, NYNPI 1285859306
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,400 of the $10,261 with a category attached, or 72.1%. Alkermes, Inc. accounts for 68.4% of it on its own, with 3 other manufacturers making up the rest. Among general practice clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 17 payments — averaging $603.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$7K
- Pfizer$2K
- F. Hoffmann-la Roche AG$1K
- Avanir Pharmaceuticals, Inc.$618
Across 757 payments — averaging $6673.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.3M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1.2M
- Sunovion Pharmaceuticals Inc.$655K
- Acadia Pharmaceuticals Inc$481K
- Supernus Pharmaceuticals, Inc.$291K
- Takeda Pharmaceuticals U.S.A., Inc.$142K
- plus $951K from 16 others
What the payments were for
- Consulting fees$7,40072%
- Travel & lodging$1,90119%
- Food & beverage$9609%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 7 | $7,019 |
| Pfizer | 4 | $1,524 |
| F. Hoffmann-la Roche AG | 1 | $1,100 |
| Avanir Pharmaceuticals, Inc. | 5 | $618 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GEODON$1,524
How this compares
$10,261 in reported general payments places this provider in the 95th percentile of 5,764 general practice providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FanaptIloperidone | 13 | $28,708 |
| TrintellixVortioxetine Hydrobromide | 14 | $13,782 |
| Paliperidone ErPaliperidone | 12 | $3,951 |
| Bupropion XlBupropion Hcl | 37 | $1,897 |
| Aripiprazole | 24 | $964 |
| Trazodone Hcl | 12 | $525 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $512 |
| Duloxetine Hcl | 26 | $360 |
| Bupropion Hcl SrBupropion Hcl | 20 | $335 |
| Clozapine | 13 | $309 |
| Buspirone Hcl | 16 | $279 |
| Lamotrigine | 13 | $253 |
| Sertraline Hcl | 29 | $218 |
| Lithium Carbonate ErLithium Carbonate | 16 | $150 |
| Clonazepam | 19 | $142 |
Paid to pharmacies, not to this prescriber.
Other general practice in Rochester
- Frank LamarRochester$34K
- James LamarRochester$32K
- Joseph DidonatoRochester$19K
- Mark HochmanHicksville$5.1M
- David RiceEast Amherst$1.2M
- Brian JacksonUtica$477K
- Ronnie MyersNew York$464K
- Ira LangsteinWhite Plains$422K
- Benedict MiragliaMount Kisco$378K
- Michael MashaalRoslyn$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.